The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Metabolomics: A New Tool to Reveal the Nature of Diabetic Kidney Disease
Abstract
Metabolomics is a field of systems biology that draws on the scientific methods of other groups to qualitatively or quantitatively characterize small molecule metabolites in organisms, revealing their interconnections with the state of the organism at an overall relative macroscopic level. Diabetic kidney disease (DKD) is well known as a chronic metabolic disease, and metabolomics provides an excellent platform for its clinical study. A growing number of metabolomic analyses have revealed that individuals with DKD have metabolic disturbances of multiple substances in their bodies. With the continuous development and improvement of metabolomic analysis technology, the application of metabolomics in the clinical research of DKD is also expanding. This review discusses the recent progress of metabolomics in the early diagnosis, disease prognosis, and pathogenesis of DKD at the level of small molecule metabolites in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Nicholson, J. K., Lindon, J. C., & Holmes, E. (1999) · Xenobiotica · doi:10.1080/004982599238047 · Cited by 3,895
MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis
Chong, J., Soufan, O., Li, C., Caraus, I., Li, S., Bourque, G., Wishart, D. S., & Xia, J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky310 · Cited by 3,629
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Beckonert, O., Keun, H. C., Ebbels, T. M. D., Bundy, J., Holmes, E., Lindon, J. C., & Nicholson, J. K. (2007) · Nature Protocols · doi:10.1038/nprot.2007.376 · Cited by 2,109
Kang, H. M., Ahn, S. H., Choi, P., Ko, Y.-A., Han, S. H., Chinga, F., Park, A. S. D., Tao, J., Sharma, K., Pullman, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3762 · Cited by 1,555
Emerging applications of metabolomics in drug discovery and precision medicine
Wishart, D. S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.32 · Cited by 1,488
Modern analytical techniques in metabolomics analysis
Zhang, A., Sun, H., Wang, P., Han, Y., & Wang, X. (2012) · The Analyst · doi:10.1039/c1an15605e · Cited by 877
Metabolomics enables precision medicine: “A White Paper, Community Perspective”
for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative, Beger, R. D., Dunn, W., Schmidt, M. A., Gross, S. S., Kirwan, J. A., Cascante, M., Brennan, L., Wishart, D. S., Oresic, M., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1094-6 · Cited by 592
Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease
Sharma, K., Karl, B., Mathew, A. V., Gangoiti, J. A., Wassel, C. L., Saito, R., Pu, M., Sharma, S., You, Y.-H., Wang, L., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020126 · Cited by 571
Review of recent developments in GC–MS approaches to metabolomics-based research
Beale, D. J., Pinu, F. R., Kouremenos, K. A., Poojary, M. M., Narayana, V. K., Boughton, B. A., Kanojia, K., Dayalan, S., Jones, O. A. H., & Dias, D. A. (2018) · Metabolomics · doi:10.1007/s11306-018-1449-2 · Cited by 531
Current practice of liquid chromatography–mass spectrometry in metabolomics and metabonomics
Gika, H. G., Theodoridis, G. A., Plumb, R. S., & Wilson, I. D. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.06.032 · Cited by 442
Diabetic nephropathy—emerging epigenetic mechanisms
Kato, M., & Natarajan, R. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.116 · Cited by 318
Gas chromatography/mass spectrometry in metabolic profiling of biological fluids
Pasikanti, K. K., Ho, P. C., & Chan, E. C. Y. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.04.033 · Cited by 302
The role of carnitine in normal and altered fatty acid metabolism
Hoppel, C. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00112-4 · Cited by 299
The role of epigenetics in the pathology of diabetic complications
Villeneuve, L. M., & Natarajan, R. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00200.2010 · Cited by 295
Nutrition, Epigenetics, and Metabolic Syndrome
Wang, J., Wu, Z., Li, D., Li, N., Dindot, S. V., Satterfield, M. C., Bazer, F. W., & Wu, G. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4381 · Cited by 261
Application of metabolomics to plant genotype discrimination using statistics and machine learning
Taylor, J., King, R. D., Altmann, T., & Fiehn, O. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.suppl_2.s241 · Cited by 249
Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study
Niewczas, M. A., Sirich, T. L., Mathew, A. V., Skupien, J., Mohney, R. P., Warram, J. H., Smiles, A., Huang, X., Walker, W., Byun, J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.497 · Cited by 225
You, Y.-H., Quach, T., Saito, R., Pham, J., & Sharma, K. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015030302 · Cited by 192
Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy
Hirayama, A., Nakashima, E., Sugimoto, M., Akiyama, S.-I., Sato, W., Maruyama, S., Matsuo, S., Tomita, M., Yuzawa, Y., & Soga, T. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6412-x · Cited by 191
Vistisen, D., Andersen, G. S., Hulman, A., Persson, F., Rossing, P., & Jørgensen, M. E. (2019) · Diabetes Care · doi:10.2337/dc19-0349 · Cited by 167
Ott, K.-H., Aranı́bar, N., Singh, B., & Stockton, G. W. (2003) · Phytochemistry · doi:10.1016/s0031-9422(02)00717-3 · Cited by 164
Biomarkers of rapid chronic kidney disease progression in type 2 diabetes
Looker, H. C., Colombo, M., Hess, S., Brosnan, M. J., Farran, B., Dalton, R. N., Wong, M. C., Turner, C., Palmer, C. N. A., Nogoceke, E., et al. (2015) · Kidney International · doi:10.1038/ki.2015.199 · Cited by 152
Extracellular Microbial Metabolomics: The State of the Art
Pinu, F. R., & Villas-Bôas, S. G. (2017) · Metabolites · doi:10.3390/metabo7030043 · Cited by 150
Special Issue “Diabetic Nephropathy: Diagnosis, Prevention and Treatment”
Ruiz‐Ortega, M., Rodrigues-Díez, R. R., Lavoz, C., & Rayego‐Mateos, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030813 · Cited by 140
Quantitative metabolic profiling based on gas chromatography.
Gates, S. C., & Sweeley, C. C. (1978) · Clinical Chemistry · doi:10.1093/clinchem/24.10.1663 · Cited by 139
Pang, L., LIANG, Q., WANG, Y., PING, L., & Luo, G. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.05.027 · Cited by 129
Zhu, C., Liang, Q., Hu, P., Wang, Y., & Luo, G. (2011) · Talanta · doi:10.1016/j.talanta.2011.05.036 · Cited by 118
Niewczas, M. A., Mathew, A. V., Croall, S., Byun, J., Major, M., Sabisetti, V. S., Smiles, A. M., Bonventre, J. V., Pennathur, S., & Królewski, A. S. (2017) · Diabetes Care · doi:10.2337/dc16-0173 · Cited by 117
Plasma glutamine and glutamic acid are potential biomarkers for predicting diabetic retinopathy
Rhee, S. Y., Jung, E. S., Park, H. M., Jeong, S. J., Kim, K., Chon, S., Yu, S., Woo, J., & Lee, C. H. (2018) · Metabolomics · doi:10.1007/s11306-018-1383-3 · Cited by 115
Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review
Li, B., He, X., Jia, W. P., & Li, H. (2017) · Molecules · doi:10.3390/molecules22071173 · Cited by 114
Epigenetic Modifications in the Pathogenesis of Diabetic Nephropathy
Reddy, M. A., Park, J. T., & Natarajan, R. D. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.05.006 · Cited by 105
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Guthrie, R. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1423852 · Cited by 102
Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy
Gordin, D., Shah, H., Shinjo, T., St-Louis, R., Qi, W., Park, K., Paniagua, S. M., POBER, D. M., Wu, I., Bahnam, V., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2585 · Cited by 98
Does Microalbuminuria Predict Diabetic Nephropathy?
Parving, H.-H., Chaturvedi, N., Viberti, G. C., & Mogensen, C. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.406 · Cited by 90
Yao, F., Li, Z., Ehara, T., Yang, L. S., Wang, D., Feng, L., Zhang, Y., Wang, K., Shi, Y., Duan, H., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.05.003 · Cited by 81
Ma, T., Liu, T., Xie, P., Jiang, S., Yi, W., Dai, P., & Guo, X. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118160 · Cited by 81
Single cell metabolomics using mass spectrometry: Techniques and data analysis
Liu, R., & Yang, Z. (2020) · Analytica Chimica Acta · doi:10.1016/j.aca.2020.11.020 · Cited by 80
A metabolomic study of low estimated GFR in non-proteinuric type 2 diabetes mellitus
Ng, D., Salim, A., Liu, Y., Zou, L., Xu, F., Huang, S. H., Leong, H., & Ong, C. N. (2011) · Diabetologia · doi:10.1007/s00125-011-2339-6 · Cited by 79
Sommerweiss, D., Gorski, T., Richter, S., Garten, A., & Kieß, W. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.10.130 · Cited by 69
Tofte, N., Suvitaival, T., Trôst, K., Mattila, I. M., Theilade, S., Winther, S. A., Ahluwalia, T. S., Frimodt‐Møller, M., Legido‐Quigley, C., & Rossing, P. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00818 · Cited by 65
Molecular mechanisms of lipotoxicity-induced pancreatic β-cell dysfunction
Benito‐Vicente, A., Jebari‐Benslaiman, S., Galicia-García, U., Larrea, A., Uribe, K. B., & Martín, C. (2021) · International review of cytology · doi:10.1016/bs.ircmb.2021.02.013 · Cited by 65
Metabolomic Profile Predicts Development of Microalbuminuria in Individuals with Type 1 Diabetes
Haukka, J. K., Sandholm, N., Forsblom, C. M., Cobb, J. E., Groop, P., & Ferrannini, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-32085-y · Cited by 58
Zhang, H., Zuo, J., Dong, S., Lan, Y., Wu, C.-W., Mao, G., & Zheng, C. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3049098 · Cited by 55
The remodel of the “central dogma”: a metabolomics interaction perspective
dos Santos, G. C., Renovato‐Martins, M., & de Brito, N. M. (2021) · Metabolomics · doi:10.1007/s11306-021-01800-8 · Cited by 54
Sargsyan, E., Artemenko, K. A., Manukyan, L., Bergquist, J., & Bergsten, P. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.06.012 · Cited by 50
Metabolomic study of the protective effect of Gandi capsule for diabetic nephropathy
Liu, Y., Chen, X., Liu, Y., Chen, T., Zhang, Q., Zhang, H., Zhu, Z., Chai, Y., & Zhang, J. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108815 · Cited by 45
Serum and urine metabolomics reveal potential biomarkers of T2DM patients with nephropathy
Shao, M., Lü, H., Yang, M. S., Liu, Y., Yin, P., Li, G., Wang, Y., Chen, L., Chen, Q., Zhao, C., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.42 · Cited by 41
Multi-Omics Analysis of Diabetic Nephropathy Reveals Potential New Mechanisms and Drug Targets
Sha, Q., Lyu, J., Zhao, M., Li, H., Guo, M., & Sun, Q. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.616435 · Cited by 40
Treatment and impact of dyslipidemia in diabetic nephropathy
Toyama, T., Shimizu, M., Furuichi, K., Kaneko, S., & Wada, T. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0898-1 · Cited by 39
Dai, X., Su, S., Cai, H.-D., Wei, D., Yan, H., Zheng, T., Zhu, Z., Shang, E., Guo, S., Qian, D., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01012 · Cited by 38
Du, Y., Xu, B., Deng, X., Wu, X., Li, Y.-J., Wang, S., Wang, Y., Ji, S., Guo, M., Yang, D., et al. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.12.017 · Cited by 38
Self-citationWu, M., Li, S., Yu, X., Chen, W., Ma, H., Shao, C., Zhang, Y., Zhang, A., Huang, S., & Jia, Z. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00076.2019 · Cited by 38
Plasma Metabolome and Lipidome Associations with Type 2 Diabetes and Diabetic Nephropathy
Tan, Y. M., Gao, Y., Teo, G., Koh, H. W. L., Tai, E. S., Khoo, C. M., Choi, K. P., Zhou, L., & Choi, H. (2021) · Metabolites · doi:10.3390/metabo11040228 · Cited by 38
Tavares, G. F., Venturini, G., Padilha, K., Zatz, R., Pereira, A. C., Thadhani, R., Rhee, E. P., & Titan, S. (2018) · Metabolomics · doi:10.1007/s11306-018-1337-9 · Cited by 37
Urine metabolites are associated with glomerular lesions in type 2 diabetes
Saulnier, P., Darshi, M., Wheelock, K. M., Looker, H. C., Fufaa, G. D., Knowler, W. C., Weil, E. J., Tanamas, S. K., Lemley, K. V., Saito, R., et al. (2018) · Metabolomics · doi:10.1007/s11306-018-1380-6 · Cited by 37
Wang, X., He, Q., Chen, Q., Xue, B., Wang, J., Wang, T., Liu, H., & Chen, X. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.113817 · Cited by 27
Devi, S., Nongkhlaw, B., Limesh, M., Pasanna, R. M., Thomas, T. S., Kuriyan, R., Kurpad, A. V., & Mukhopadhyay, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-54584-2 · Cited by 26
Metabolomics analysis for diagnosis and biomarker discovery of transthyretin amyloidosis
Olsson, M. B., Hellman, U., Wixner, J., & Anan, I. (2021) · Amyloid · doi:10.1080/13506129.2021.1958775 · Cited by 21
Chen, S., Liu, Y., Dai, D., Zhu, Z., Dai, Y., Wu, Z., Zhang, L.-P., Duan, Z.-F., Lu, L., Ding, F., et al. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02268-3 · Cited by 20
Zhang, F., Guo, R., Cui, W., Wang, L., Xiao, J., Shang, J., & Zhao, Z. (2021) · Renal Failure · doi:10.1080/0886022x.2021.1937219 · Cited by 18
Cited by
UniProt: the Universal Protein Knowledgebase in 2023
The UniProt Consortium, Bateman, A., Martin, M.-J., Orchard, S., Magrane, M., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., Bye-A-Jee, H., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1052 · Cited by 7,210
KEGG for taxonomy-based analysis of pathways and genomes
Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M., & Ishiguro-Watanabe, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac963 · Cited by 5,833
Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chao, H., Chen, L., Craig, P. A., Crichlow, G. V., Dalenberg, K., Duarte, J. M., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1077 · Cited by 887
TTD: Therapeutic Target Database describing target druggability information
Zhou, Y., Zhang, Y., Zhao, D., Yu, X., Shen, X., Zhou, Y., Wang, S., Qiu, Y., Chen, Y., & Zhu, F. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad751 · Cited by 645
Challis, R., Kumar, S., Sotero-Caio, C., Brown, M., & Blaxter, M. (2023) · Wellcome Open Research · doi:10.12688/wellcomeopenres.18658.1 · Cited by 620
Metadata
- Authors
- Huang, G., Li, M., Li, Y., & Mao, Y.
- Venue
- Laboratory Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-06-24
- Volume
- 53
- Issue
- 6
- Pages
- 545-551
- ISSN
- 0007-5027 (ISSN-L)
- 1943-7730
- OpenAlex
- W4205440119
- Cited by
- 922
- References
- 64
- FWCI
- 63.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.